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Summary: A homogeneous enzyme immunoassay for the determination of methotrexate in serum (EMIT, Syva
Corp.) was fully mechanized by the use of an Eppendorf analyzer 5010. Coefficients of variation from day to day
were in the range 2-16%. A comparison of the results obtained by EMIT and a radioimmunoassay (Methotrexate
125I Radioimmunoassay Kit, Diagnostic Biochemistry Inc.) in a series of 50 samples from patients showed a good
correlation between both methods. The specificity of the EMIT assay appeared to be adequate. The time required
for the determination of about 20 patient samples by this procedure was only about 80 minutes. From our clinical
experience the EMIT assay appears to be well suited for routine monitoring of methotrexate serum concentrations
above 0.1 μπιοΐ/l during intrathecal and high dose methotrexate therapy.
Bestimmung von Methotrexat im Serum mit einem rasch durchf hrbaren, vollmechanisierten Enzymimmunotest
(EMIT)
Zusammenfassung: Ein homogener Enzymimmunotest zur Bestimmung von Methotrexat im Serum (EMIT, Syva
Corp.) wurde mit Hilfe eines Eppendorf Enzyrnautomaten 5010 vollmechanisiert. Die Variationskoeffizienten von
Tag zu Tag lagen bei etwa 2—16%. Ein Vergleich der Ergebnisse, welche mit EMIT und einem Radioimmunotest
(Methotrexate 125I Radioimmunoassay Kit, Diagnostic Biochemistry Inc.) bei einer Serie von 50 Patientenproben
erhalten wurden, ergab eine gute Korrelation beider Verfahren. Die Spezifit t des EMIT-Tests erschien ausreichend.
F r die Bestimmung von 20 Patientenproben w rden mit diesem Verfahren nur etwa 80 Minuten ben tigt. Nach
unseren klinischen Erfahrungen scheint der EMIT-Test bei der intrathekalen und hochdosierten Methotrexat-Therapie
gut zur routinem igen berwachung von Methotfex t-Konzentrationen im Serum ber 0,1 μηιοΐ/ΐ geeignet zu sein.
Introduction
Methotrexate^), an inhibitor of dihydrof late reductase
(EC 1.5.1.3), is widely used in the chemotherapy of
various ne plastic diseases, such as breast cancer, acute
leucaemia or osteogenic sarcoma, and in the treatment
of nonrfieoplastic disorders such as severe psoriasis (1).
With systemic and intrathecal regimens for methotrexate
in current use, serious toxicities such as myelosuppres-
sion, gastrointestinal mucositis, renal failure and neuro-
*) Parts of this study have been reported at "Kongre der
Deutschen Gesellschaft f r Laboratoriumsmedizin" in
Berlin 1979.2) 4-Amiho-N10-methyHpteroylgl tamic acid (amethopterin).
Abbreviation: EMIT® = enzyme multiplied immunoassay
technique.
toxicity have been observed (1). Especially patients who
receive high-dose methotrexate regimens risk the develop-
ment of life-threatening side reactions. Toxicity occurs
if certain thresholds for the duration of methotrexate
exposure and the serum concentration of this compound
are exceeded. For bone marrow and gastrointestinal
epithelium, for example, these thresholds appear to be
0.02 jumol/1 and about 42 hours (1). The severity of
toxicity depends more on the extent to which the time-
threshold is exceeded than on the magnitude of the
elevation of the methotrexate concentration above the
concentration-threshold (1). According to the literature
serum methotrexate levels < 5-10 μτηοΙ/1 at 24 hours
(2, 32), < 0.5-1.0 μπιοΐ/l at 48 hours (2-4) and < 0.05
jumol/1 at 72 hours (2) after initiation of the methotrexate
therapy point to an adequate' serum methotrexate
clearance and usually will not produce toxicity.
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Monitoring of serum niethotrexate concentrations may
be helpful in the identification of patients with elevated
methotrexate levels. Life-threatening side reactions may
then be averted by administration of the antidote citro-
vorum factor (5-formyltetrahydrofolate; trade name:
leucovorin), and by taking measures to improve renal
methotrexate excretion, such as intravenous hydration
and alkalinization of the urine (1). Furthermore, the
methotrexate serum levels can be monitored, so that the
administration of citrovorum factor is continued until
the methotrexate concentration has fallen below the
toxicological relevant borderline at about 0.08—0.1
μτηοΐ/ΐ (1), preferably below 0.01 μιηοΐ/ΐ (3, 5).
Monitoring of serum methotrexate levels has been
recommended recently by various authors (1—7). So
far, for the determination of methotrexate, relatively
complex microbiological (7), fluorometric (8, 9),
enzymatic (10,11) and high-pressure liquid Chroma-
tographie (12,13) methods have been used. A dis-
advantage of competitive protein binding assays (14,
15) and radioimmunoassays (16, 17) is that these
methods require the use of radioactive material. Recently
a homogeneous enzyme immunoassay for the determi-
nation of methotrexate (18) has become commer-
cially available (EMIT Methotrexate Assay, Syva Corp.,
Palo Alto, U.S.A.). In the present study we report on an
evaluation of a mechanized version of this EMIT assay
and our preliminary clinical experience with this test.
Material and Methods
Origin of specimens
Serum samples (n = 168) containing methotrexate were obtained
from patients with various neoplastic diseases such as breast
cancer, acute lymphocytic leucaemia and osteogenic sarcoma.
Materials
The reagents for the enzyme immunoassay (EMIT), the deter-
mination of aspartate aminotransferase (EC 2.6.1.1; Merckotest
No. 3375), alanine aminotransferase (EC 2.6.1.2; Merckotest
No. 3376), hypoxanthine and adenine were obtained from
E. Merck (D-6100 Darmstadt), the Methotrexate 125I Radio-
immunoassay Kit from Diagnostic Biochemistry Inc. (San Diego,
U.S.A.), methotrexate, calcium N5-formyltetrahydrofolate and
thiotepa from Cyanamid (D-8190 Wolfratshausen), aminopterin,
folic acid, dihydrofolic acid, tetrahydrofolic acid and barium
N5-methyltetrahydrofolate from Sigma (D-8021 Taufkirchen),
6-mercaptopurine, allopurinol and azathioprine from Wellcome
(D-3006 Burgwedel 1), trimethoprim from Ratiopharm (D-7902
Blaubeuren), daunorubicin, doxorubicin from Montedison
Farmazeutica (D-7800 Freiburg), cyclophosphamide from Asia
(D-4800 Bielefeld 14), 5-fluorouracil from Hoffmann-La-Roche
(D-7889 Grenzach-Wyhlen), vincristine and vinblastine from
Lilly (D-6380 Bad Homburg), colchicine from Kali-Chemie
(D-3000 Hannover 1), cytarabine from Mack (D-7918 Iller-
tissen), 4-Amino-4-deoxy-N10-methylpteroic acid and
7-hydioxymethotrexate were obtained from Syva Corp.,
Palo Alto, U.S.A.
Enzyme immunoassay (EMIT)
The original procedure of the EMIT methotrexate assay was
fully mechanized by adapting this test to the Eppendorf analyzer
5010 (Eppendorf, D-2000 Hamburg) in the same way as pre-
viously described for the EMIT assays of phenobarbital, pheny-
toin and theophylline (19, 20).
Radioimmunoassay
Methotrexate determinations by radioimmunoassay were carried
out by use of the Methotrexate 125I Radioimmunoassay Kit
according to the instructions of the manufacturer.
Results and Discussion
Precision
The coefficients of variation from day to day were
2-16% with EMIT (tab. 1) and with the radioimmuno-
assay about 10% (mean value with standard deviation:
1.02 ± 0.11 μιηοΙ/1, number of contributing values: 5).
The precision data of EMIT and radioimmunoassay refer
to mean values of duplicate determinations and single
determinations respectively.
Tab. 1. The precision from day to day of the EMIT assay for
determination of methotrexate in serum. Assays were
performed in duplicate on 24 days and the mean values






























a) Mean value (x) with coefficient of variation
b) EMIT methotrexate control (Syva)
Accuracy
The recovery of methotrexate added to drug-free pooled
human serum (concentration range 0.3—1.9 μπιοΙ/1) with
EMIT was 100-107%, and with the radioimmunoassay
was 105-120% (tab. 2).
Furthermore the results measured by EMIT and radio-
immunoassay in 50 specimens from patients were com-
pared. The correlation between the results was good
(r = 0.974). The slope of the line and the intercept were
calculated by use of the standardized principal component
analysis (21, 22), which in contrast to the classical regres-
sion analysis represents a bivariate procedure. The slope
of the line points to a proportional difference of about
10% (fig. 1). Accordingly the mean value of the results
obtained by EMIT (y: 0.48 ± 0.36 jumol/1) was signifi-
cantly lower than that of the values determined by radio-
immunoassay (x: 0.53 ± 0.40 μτηοΐ/ΐ; t-value 3.45,
ρ <°0.0025). This discrepancy appears to be due to the
elevated recovery of me<thotrexate by the radioimmuno^
assay (tab. 2). Reproducible deviations of more than
30% between the results of both assays occurred in 2
out of 50 cases.
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Tab. 2. The recovery of methotrexate by EMIT and radio-
immunoassay in spiked serum samples. Determinations
were performed by EMIT on five and by radioimmuno-
assay on three days.
Tab. 3. Cross-reactivity of various substances in seruma) with












































a) Mean value and number of contributing values in parenthesis
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2D
Methotrexate (Radioimmunoassay) [jimol/l]
Fig. 1. Serum methotrexate concentrations as measured by
EMIT and radioimmunoassay (n = 50). Slope: 0.897.
Intercept: 0.008 μηιοΐ/ΐ, correlation coefficient: 0.974.
Specificity
The specificity of the EMIT assay was teste.d by the
determination of the cross-reactivity of compounds
structurally related to methotrexate and various other
drugs. Aminopterin caused a relevant cross-reaction in
this assay (tab. 3). This drug, however, is usually not
administered together with methotrexate.
Folic acid, dihydrofolic acid, N5-formyltetrahydro-
folate and N5-methyltetrahydrpfolate showed a notice-
able cross-reactivity only at concentrations, which were
about 3-5 orders of magnitude above the normal range
for serum levels of folic acid and its derivatives (16).
After intramuscular or oral administration of 15 mg
citrovorum factor, serum concentrations of N5-formyl-
tetrahydrofolate and its metabolite N5-methyltetrar
hydrpfplate reached peak levels of less than 2 μπιοΐ/ΐ
(23). Accordingly no false positive results were obtained
with patients (n == 3) receiving no methotrexate, when
a standard dose of 15 mg citrpvprum factor was repeated^
ly intravenously administered, or elevated serum concen-
trations of folate (30-50 nrnpl/1) were present.

































































a) Substances were added to drug-free pooled human serum
b) Concentration producing a deviation of 30% from the
expected value in a sample containing 1.0 Mmol/l metho-
trexate.
In accordance with the manufacturer (24) we observed
that the metabolites of methotrexate, 4-amino-4-deoxy-
N10-methylpteroic acid and 7-hydroxymethotrexate,
which show only a relatively weak cytostatic effect (5),
interfere distinctly at concentrations above 0.4 μπιοΐ/ΐ
and 90 /zmol/l respectively (tab. 3). As 7-hydroxymetho-
trexate levels were reportedly below 90 jumol/1 during
high-dose methotrexate-therapy (13), a relevant inter-
ference of this metabolite usually appears to be improb-
able. It is not known whether serum 4-amino-4-deoxy-
N10-methylpteroic acid (25) occurs in sufficiently high
concentration to cause an interference.
With the remaining substances tested (tab. 3) no relevant
cross-re activity was observed.
Interferences
In spiked serum samples bilirubin (up to 600 μτηοΐ/ΐ),
haemoglobin (up to 10 g/1) and triglycerides (up to
12 mrnol/1) caused deviations of less than 10% from the
expected methotrexate values in the EMIT assay.
Detectability
The detection limit of methotrexate by EMIT was
approximately at 0.1 μτηοί/Ι. At this methotrexate con-
centration a coefficient of variation of about 30% (mean
J. Clin. Chem. Clin. Biochem. /Vol. 18,1980 / No. 3
172 Oellerich, Engelhard t, Schaadt and Diehl: Determination of methotrexate by enzyme immunoassay
value: 0.11, n = 10) was found within series. Though the
detection limit of the EMIT assay is about 3 orders of
magnitude above that of the radioimmunoassay, the
EMIT assay usually appears to be sensitive enough for
routine monitoring of methotrexate concentrations
during the first decisive 48—72 hours after high dose
administration of methotrexate, or the time until the
level of this drug has fallen below 0.1 μπιοΐ/l. As metho-
trexate, however, inhibits DNA synthesis in bone marrow
and intestinal epithelium at concentrations above 0.01
Mmol/l (26), it appears necessary to monitor metho-
trexate concentrations down to this level in patients
showing manifest (3) or questionable toxicity. There^
fore the detectability of the EMIT assay has to be
adequately improved.
Practicability and costs
Compared with the radioimmunoassay, the EMIT test
showed better practicability. A disadvantage of the radio-
immunoassay is that one or more dilutions have to be
prepared from every sample, as the calibration curve
ranges from 0.2-4.4 nmol/1. The time required for the
determination of about 20 patients samples containing
methotrexate concentrations within the clinically relevant
range of 0.1—2.0 Afmol/1 is about 80 minutes by our fully
mechanized modification of the EMIT assay, and ap-
proximately 270 minutes by radioimmunoassay.
A single methotrexate determination for emergency
situations can be performed by EMIT within 40 and
by radioimmunoassay in about 80 minutes.
As already frequently pointed out (30, 31), the EMIT
technique has the advantage that contact with radio-
active material is avoided, the reagents have a long shelf-
life and its mechanization is easy. Compared with the
original procedure our fully mechanized version of the
EMIT assay shows better practicability, a higher sample
throughput per hour and a reduction of costs for rea-
gents and technician time by about 20—40% (based on a
series of 10-30 patients samples). The costs for a metho-
trexate determination including standards, control sera,
reagents, pertinent supplies and technician time are
about 14 DM per EMIT test and about 13 DM with the
radioimmunoassay, for a series of 20 samples. A single
methotrexate determination is much more expensive
(tab. 4).
Clinical experience
Methotrexate serum concentrations were determined by
EMIT in samples from patients (n = 5) who repeatedly
received an intrathecal injection of 25 mg methotrexate
(= 12—16 mg/m2) once a week because of diffuse,
leptomeningeal infiltrations due to acute lymphocytic
leucaemia, malignant lymphoma or breast carcinoma.
With all of these patients only relatively low serum
methotrexate concentrations were observed (tab. 5), and
Tab. 4. Comparison of the costs of a quantitative determination
of methotrexate by EMIT adapted to the Eppendorf



















a)' N = number of specimens per series
b) zero calibrator and sample analyzed in duplicate, single
measurements of all other calibrators
c) all samples and calibrators analyzed in duplicate
d> costs per minute technician time 0.60 DM (27)
Tab. 5. Serum concentrations in patients (n = 5) repeatedly
treated with an intrathecal methotrexate dosage of































a) median and range are given as the contributing values did not
show a normal distribution
b) number of contributing values
48 hours after intrathecal administration of this com-
pound methotrexate serum levels were always below
0.1 μχηοΐ/ΐ. Accordingly no relevant adverse reactions
occurred with these patients. The serum methotrexate
concentrations observed (tab. 5) after intrathecal injec-
tion of this substance are of the same order of magnitude
as those described in the literature (28).
The EMIT assay also appears to be well suited for moni-
toring of serum methotrexate levels during high-dose
methotrexate therapy. In figure 2 the time course of the
serum methotrexate concentrations in a 20 year old
female patient with osteogenic sarcoma during and
after the infusion of 250 ing/kg methotrexate is
illustrated. Citrovoram factor (15 mg) was given as
indicated every six hours. Intravenous hydration {glucose
50 g/1 (Travenol) 1500 ml/24 hours; ringer-lactate solu-
tion (Braun Mels ngen) 1500 ml/24 hours) and alkalini-
zation (NaHCO3-solution 60 iramol/24 hours) was started
12 hours before the beginning of the methotrexate infu-
sion and then maintained for a further 72 Hours. The
J. Clin. Chem. Clin. Biochem. / Vol. 18,1980 / No. 3
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Fig. 2. Serum methotrexate concentrations in a 20 year old
female patient with osteogenic sarcoma during and after
a four hour period of infusion of 250 mg/kg metho-
trexate. Citrovorum factor (15 mg) was given as indicated
by arrows every six hours.
creatinine clearance of the patient (132 ml/min) was in
the normal range. The serum methotrexate levels at
24 and 48 hours after the beginning of the metho-
trexate infusion were below the corresponding toxi-
cologically relevant borderlines of ΙΟμτηοΙ/Ι and 1.0
μπιοΐ/ΐ respectively. Accordingly no relevant adverse
reactions were observed. At 72 and 96 hours, however,
the serum methotrexate levels were distinctly above
0.1 μηιοΐ/l and a transient rise of alanine aminotrans-
ferase (up to 108 U/l) and of aspartate aimnptransferase
(up to 63 U/l) occurred. A myelosuppression was not
encountered. The methotrexate levels determined by
EMIT at 24 and 48 hours were in accordance with those
observed by other authors at the same dosage of this
drug (1—4). The slightly elevated methotrexate concern
trations at 72 and 96 hours might be due to a release of
methotrexate from storage sites. Wang et al. observed in
some patients even higher methotrexate plasma concen-
trations at 72 hours than at 48 hours, presumably due to
such a phenomenon (29).
During the terminal serum disappearance phase of metho-
trexate, following its high-dose administration, an in-
creased concentration of methotrexate metabolites in
the serum is to be expected (1). This may be important
in the genesis of toxic adverse reactions (1) and might
cause an interference in enzyme- and radioimmunoassays
for the determination of methotrexate (24, 25). There-
fore it appears necessary to investigate the serum concen-
trations of 4-amino-4-deoxy-N10-methylpteroic acid and
7-hydroxymethotrexate, the major metabolites of
methotrexate, during this period. As high-pressure liquid
chromatography has already been successfully applied
to the determination of 7-hydroxymethotrexate (13),
it is planned to use this technique in further studies on
serum concentrations of methotrexate metabolites.
Conclusion
Compared with other procedures used so far for metho-
trexate determination, the EMIT assay has the advantage
that it can be more easily mechanized and rapidly per-
formed. The detectability of the EMIT assay needs to be
improved somewhat, in order to detect methotrexate
concentrations above 0.01 /imol/l; relevant studies are
in progress. Except for this limitation the EMIT assay
proved to be dependable and appeared to be well suited
for routine monitoring of serum methotrexate concen-
trations during intrathecal and high-dose methotrexate
therapy.
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Note added to the proof
After completion of the experiments a new lot of this EMIT
assay was obtained, in which the linearity range was reduced
to 1.5 /unol/1.
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